JPRN-C000000264已完成2 期
Second-line Trastuzumab/Docetaxel combination therapy in patients with HER2-positive metastatic breast cancer(MBC)- a phase 2 study - Second-line Trastuzumab/Docetaxel combination therapy in patients with HER2-positive metastatic breast cancer(MBC)- a phase 2 study(Beyond PD study)
H/D study group on Breast Cancer0 个研究点目标入组 35 人开始时间: 2005年10月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Documented history of serious hypersensitivity reaction on the medical drugs Severe complication Fever, suspicious of infection Severe pleural fluid and pericardial effusion Symptomatic brain metastasis Active double cancer Interstitial pneumonia or pulmonary fibrosis Neuropathy Grade 2,3 or 4 edema Pregnant or lactating women Doctor's decision for exclusion
研究者
相似试验
已完成
2 期
Phase 2 study of trastuzumab and docetaxel therapy for HER2-positive recurrent/metastatic salivary gland carcinomaHER2-positive salivary gland carcinomaJPRN-UMIN000018165Hokkaido University Hospital16
已完成
2 期
A phase II study of trastuzumab added to docetaxel and S-1 for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer.gastric cancerJPRN-UMIN000005366Okayama University40
进行中（未招募）
不适用
trastuzumab, docetaxel and oxaliplatino association in metastatic breast cancer with her2 receptor overexepression Phase II clinical trial - HOTEUCTR2006-000413-37-ITAZIENDA UNITA SANITARIA LOCALE N 12 DI VIAREGGIO50
已完成
2 期
Phase II trial of trasutuzumab plus docetaxel for previous trastuzumab treated unresectable or recurrent HER2 positive gastric cancer (T-CORE1203)HER2 positive gastric cancerJPRN-UMIN000010869Tohoku Clinical Oncology, Research and Education Society(T-CORE)27
已完成
不适用
Docetaxel and Trastuzumab therapy or maximal androgen blockade for patients with recurrent and/or metastatic salivary grand carcinomaHER2 and/or androgen receptor positive recurrent and/or metastatic salivary gland carcinomaJPRN-UMIN000009437International University of Health and Welfare Mita Hospital30